Cyp2c66 inhibitors are a specialized class of chemical compounds designed to selectively inhibit the activity of the Cyp2c66 enzyme, a member of the cytochrome P450 superfamily. The Cyp2c66 enzyme is involved in the oxidative metabolism of a diverse range of substrates, including endogenous molecules such as lipids, hormones, and other signaling compounds, as well as exogenous substances like drugs and environmental chemicals. This enzyme catalyzes the monooxygenation of these substrates, a biochemical process that involves the insertion of an oxygen atom into the substrate molecule. This oxidative modification generally increases the substrate's solubility, making it more amenable to further metabolic processing, such as conjugation and eventual excretion from the body. Cyp2c66, like other cytochrome P450 enzymes, plays a critical role in detoxification pathways and the regulation of metabolic processes, particularly in tissues such as the liver where these enzymes are most active.
Inhibitors of Cyp2c66 are typically small molecules that are designed to bind specifically to the enzyme's active site, preventing it from interacting with and metabolizing its natural substrates. These inhibitors may function by occupying the substrate-binding pocket, thereby blocking the access of substrates to the catalytic site, or by inducing conformational changes that reduce the enzyme's catalytic efficiency. The development of Cyp2c66 inhibitors involves detailed structural studies of the enzyme, focusing on the identification of key regions involved in substrate binding and catalysis. By inhibiting Cyp2c66, researchers can explore the enzyme's specific role in various metabolic pathways and gain insights into how its inhibition affects the broader network of cytochrome P450-mediated reactions. The study of Cyp2c66 inhibitors is crucial for understanding the enzyme's substrate specificity, its interactions with other metabolic enzymes, and its overall contribution to maintaining metabolic homeostasis within the body. This research deepens our knowledge of the functional diversity within the cytochrome P450 superfamily and underscores the importance of these enzymes in the metabolism and detoxification of a wide range of chemical entities in biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Antifungal agent in research acting as a direct inhibitor of CYP2C66 by interfering with monooxygenase activity. Modifies intracellular membrane functions, hindering the enzyme's predicted activity in caffeine oxidase pathways. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $52.00 $87.00 | 7 | |
Alcohol deterrent indirectly inhibiting CYP2C66 by impacting caffeine oxidase activity. Disrupts intracellular membrane-bounded organelle functions, influencing the enzyme's predicted involvement in heme binding. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $53.00 $84.00 | 14 | |
Antifungal agent acting as a direct inhibitor of CYP2C66 by interfering with monooxygenase activity. Alters membrane-bounded organelle dynamics, hindering the enzyme's predicted participation in caffeine oxidase pathways. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
H2 receptor antagonist indirectly inhibiting CYP2C66 by modulating monooxygenase activity. Disrupts cytoplasmic and intracellular membrane functions, influencing the enzyme's predicted involvement in heme binding. | ||||||
Enoxacin | 74011-58-8 | sc-205670 sc-205670A | 500 mg 1 g | $39.00 $48.00 | 2 | |
Fluoroquinolone antibiotic acting as a direct inhibitor of CYP2C66 by affecting caffeine oxidase activity. Modifies endoplasmic reticulum dynamics, hindering the enzyme's predicted participation in heme binding processes. | ||||||
Phenylbutazone | 50-33-9 | sc-204843 | 5 g | $31.00 | 1 | |
Nonsteroidal anti-inflammatory drug directly inhibiting CYP2C66 by suppressing monooxygenase activity. Modifies intracellular membrane dynamics, impacting the enzyme's predicted participation in heme binding processes. | ||||||
Trimethoprim | 738-70-5 | sc-203302 sc-203302A sc-203302B sc-203302C sc-203302D | 5 g 25 g 250 g 1 kg 5 kg | $66.00 $158.00 $204.00 $707.00 $3334.00 | 4 | |
Antibiotic acting as a direct inhibitor of CYP2C66 by affecting caffeine oxidase activity. Modifies endoplasmic reticulum dynamics, hindering the enzyme's predicted involvement in heme binding pathways. | ||||||
Econazole | 27220-47-9 | sc-279013 | 5 g | $240.00 | ||
Antifungal agent acting as a direct inhibitor of CYP2C66 by interfering with monooxygenase activity. Modifies membrane-bounded organelle functions, hindering the enzyme's predicted participation in caffeine oxidase pathways. | ||||||
Ranitidine | 66357-35-5 | sc-203679 | 1 g | $189.00 | ||
H2 receptor antagonist indirectly inhibiting CYP2C66 by modulating monooxygenase activity. Alters cytoplasmic and intracellular membrane-bounded organelle functions, influencing the enzyme's predicted activity in heme binding. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $312.00 | 9 | |
Selective serotonin reuptake inhibitor indirectly impacting CYP2C66 by suppressing caffeine oxidase activity. Influences intracellular membrane dynamics, hindering the enzyme's predicted involvement in heme binding. | ||||||